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Biosurgical Hemostasis in Thoracic 




Patients undergoing cardiothoracic surgery, especially open cardiac procedures 
requiring cardiopulmonary bypass, are exposed to several alterations in primary 
and secondary hemostasis. These derangements are associated with increased 
microvascular bleeding that is refractory to conventional surgical maneuvers aimed 
at achieving hemostasis. This poses a technical problem for the surgeon and exposes 
the patient to increased morbidity from uncontrolled bleeding and any associated 
transfusion of blood products. Use of biosurgical hemostatic agents, specifically 
in patients undergoing cardiac surgery, have been shown to be safe and effective 
in reducing time to hemostasis, decreasing transfusion of blood products, and 
improving patient outcomes. Despite their merits, selection of a topical hemostat 
is frequently based on anecdotal experience and limited knowledge of the avail-
able agents. The prepared surgeon is familiar with these agents and can anticipate 
opportunities for their deployment in the setting of coagulopathy.
Keywords: cardiothoracic surgery, biosurgical agents, topical hemostatic agents, 
surgical hemostasis, blood conservation
1. Introduction
In the United States, national data has shown that cardiac surgical procedures uti-
lize somewhere between 10 and 15% of the approximately 15 million units of packed 
red blood cells received by surgical patients annually [1]. To this point, the Society of 
Thoracic Surgeons (STS) published a series of blood conservation guidelines in 2007 
and 2011 aimed at cardiac surgery procedures [2, 3]. These guidelines developed a risk 
profile of factors associated with increased post-operative blood transfusion such as: 
advanced age, reduced preoperative red blood cell volume, utilization of antiplatelet 
or antithrombotic drugs, procedural factors (including the complexity, urgency, or 
re-operative nature of the surgery), and non-cardiac patient comorbidities. With these 
high risk factors identified, a set of evidence-based blood conservation guidelines were 
establish to include: utilization of medications to increase preoperative blood volume 
(eg, erythropoietin) or decrease post-operative blood loss (eg, anti-fibrinolytics), 
intra-operative blood salvage or sparing techniques, autologous pre-donation to reduce 
stress upon the patient’s own blood, transfusion algorithms and recommendations 
for a multimodality approach that utilizes all of the above. The subsequently revised 
guidelines in 2011 included: pre-operative management of dual-antiplatelet therapy, 
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utilization of drugs that augment blood volume or limit blood loss, use of blood 
derivatives (eg, fresh frozen plasma, coagulation factor concentrates, etc.), updates 
in the management of blood salvage techniques, consideration for minimally invasive 
techniques to limit blood loss or transfusion, recommendations for blood conservation 
in conjunction with extra-corporeal membrane oxygenation and cardiopulmonary 
bypass, and implementation of topical hemostatic agents. Despite these measures, 
there has been an increase in blood product utilization by patients undergoing cardiac 
surgery procedures over the last decade. The reasons likely being multifactorial but 
include a rise in number of patients undergoing complex, multiple component cardiac 
surgeries (e.g., CABG and valve procedure), increased number of patients exposed to 
clopidogrel or similar strong anti-platelet medications, and removal of aprotinin from 
the US market in 2007. Aprotinin is an anti-fibrinolytic serine protease that has been 
shown to decrease blood product transfusion in CABG patients by nearly 39% [4]. 
However, further research demonstrated increased patient morbidity and mortality 
and it was subsequently removed from the market. Subsequent studies have shown 
increased transfusion requirements in cardiac surgery patients since its removal [5].
The effect of blood product transfusion on cardiac surgery patients has been well 
studied in the literature and associated with incremental morbidity as defined by 
renal failure, prolonged ventilator support, serious infection, cardiac complications 
or neurologic events for each unit transfused [6]. Recent data investigating patients 
undergoing coronary surgery associated intra-operative transfusion with a more than 
three-fold increase in 30-day mortality [7]. By comparison, less has been written about 
blood product transfusion in general thoracic procedures. However, the available data 
echoes much of what has been described in cardiac surgery. A large retrospective study 
by Ferraris, et al. analyzed 8728 patients undergoing non-vascular thoracic procedures. 
The study found an adverse, dose-dependent relationship between intra-operative 
blood transfusions and morbidity, pulmonary complications, sepsis, wound com-
plications, and length of stay [8]. Given the increased utilization of blood products 
in cardiac patients and the associated risks of transfusion, it is important to identify 
patients at risk for bleeding complications following cardiac surgery.
Bleeding is a significant complication of open cardiac surgery, with an incidence 
ranging from approximately 5–15%. Cardiac surgery procedures are associated with 
significant alterations in physiology compared to non-cardiac thoracic surgery. 
Cardiopulmonary bypass (CPB) and exposure of the patient’s blood to a non-
endothelialized circuit has been associated with stimulation of both intrinsic and 
extrinsic coagulation pathways. To counteract this, patients are systemically heparin-
ized. Cardiopulmonary bypass is likewise associated with platelet dysfunction and 
consumption secondary to platelet adhesion to surfaces, hemodilution, and platelet 
aggregation. CPB associated thrombocytopenia is further exacerbated by the process 
of intra-operative red blood cell salvage. After blood is aspirated from the surgical 
field, it is collected in a sterile reservoir and processed. The process of centrifugation 
separates red blood cells from platelets and plasma which are both removed as waste. 
The isolated red blood cells are then washed of debris in anticipation of reinfusion 
and therefore without a component of plasma or platelets. Following initiation of 
CPB, cardioplegia is achieved and patients are cooled for the cardioprotective effects 
of hypothermia which impair the enzymatic reactions of the coagulation cascade. In 
a recent study, aortic procedures were associated with the highest bleeding complica-
tion rate (15.0%) and isolated CABG with the lowest risk (5.1%). Complications from 
bleeding were associated with increased LOS and critical care utilization. Patients 
undergoing re-exploration for bleeding demonstrate larger increases in both LOS 
and days spent in critical care [9]. Naturally, the significant consumption of health-
care resources following these complications translates to an incremental economic 
burden on both the patient and the healthcare system. In adult cardiac surgery 
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patients undergoing re-exploration for bleeding, a meta-analysis by Biancari, et al. 
sought to characterize sources of bleeding identified at the time of re-exploration. 
They collected data from 18 different studies, a total of 51497 patients where 2455 had 
undergone reoperation for bleeding/tamponade. Of these patients, surgical sources of 
bleeding were identified in 65.7% of patients in comparison to diffuse bleeding which 
can be more troublesome. Bleeding was further delineated as cardiac/bypass graft 
(40.9%) or mediastinal (pericardial, sternal, etc.) (27.0%). The predominant sites 
identified were: the body of the graft (20.2%), the sternum (17.0%), vascular suture 
lines (12.5%), the internal mammary harvest site (13.0%) and anastomoses (9.9%) 
[10]. Alternatively, diffuse bleeding, often attributed to coagulopathy secondary to 
anti-thrombotic agents can represent a significant challenge in achieving hemostasis 
with increased risk for residual blood loss and transfusion of blood products. Biancari 
et al., suggest that re-exploration for bleeding in cardiac surgery patients may be a 
preventable event with systematic evaluation of these areas and meticulous hemosta-
sis prior to closure. Biosurgical hemostatic agents may serve as valuable adjuncts in 
this process and in the reduction of bleeding complications.
Topical hemostatic agents are useful adjuncts to reducing operative and post-
operative bleeding and play an essential role in cardiothoracic surgery procedures. 
Patients presenting for cardiac surgery, as opposed to non-cardiac thoracic surgery, 
have likely been exposed to antiplatelet agents such as aspirin, clopidogrel, ticagrelor, 
apciximab or systemic anticoagulation agents such as warfarin or heparin (including 
intra-operative bolus dosing and subsequent reversal with protamine). Furthermore, 
patients undergoing cardiac procedures utilizing cardiopulmonary bypass are even 
more prone to bleeding and blood product transfusion [11]. In patients undergoing 
cardiothoracic surgery, non-surgical bleeding, defined as microvascular bleeding 
secondary to coagulopathy or capillary oozing can limit the utility of conventional 
surgical maneuvers in achieving hemostasis such as suture ligation, electrocautery, 
and surgical clips. The presence of non-surgical bleeding due to coagulopathy should 
be primarily directed at correction of the underlying abnormality but also presents 
an opportunity for the utilization of biosurgical hemostatic agents which can serve 
as useful adjuncts in gaining adequate hemostasis.
Selection of a hemostatic agent is often anecdotal and the following review 
seeks to clarify the available agents, their mechanisms, efficacy, and potential risks 
associated with their use. Conceptually, biosurgical hemostatic agents can be broadly 
classified as active, non-active, or a combination of both. A hemostatic agent is 
considered active if it contains agents directly involved in the clotting cascade such as 
thrombin in isolation or combined with a mechanical agent. In contrast, non-active 
agents contain no clotting factors, rather they provide a mechanical or synthetic seal 
to aid in achieving hemostasis. Lastly, there are a few available agents which utilize 
elements of both major categories that are known as flowable hemostatic agents.
2.  Thrombin with or without gelatin carrier (Thrombin JMI®, 
Evithrom®, and Recothrom®)
Thrombin is an endogenous serum protease formed from its precursor prothrom-
bin during activation of the intrinsic and extrinsic coagulation pathways. Thrombin 
is involved in the cleavage of fibrinogen to fibrin which polymerizes to serve as the 
basis of a hemostatic clot. Thrombin concurrently activates factor XIII which aids 
in fibrin crosslinking and strengthening the polymerized fibrin mesh to complete 
the clot atop the platelet plug, thereby achieving hemostasis. Historically, throm-
bin was isolated from bovine plasma with well documented reports of producing 
clinically significant antibody responses and hemorrhagic complications (excessive 
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post-operative bleeding and re-operation for bleeding) following patient exposure. 
Typically, patients develop antibodies to bovine factor V and Va, with more than half 
of patients producing auto-antibodies to human coagulation proteins, specifically 
factor V which can produce life-threatening bleeding [12]. In response to these con-
cerns, both human derived and recombinant human thrombin have been developed. 
An unpublished phase III, prospective randomized controlled double-blinded study 
demonstrated that human-derived thrombin was as effective as bovine-derived 
thrombin in providing effective hemostasis. In this study, human-derived thrombin 
was applied to a gelatin sponge and produced effective hemostasis in 93.6% of 
cardiovascular surgery patients within 6 minutes and 61.7% within 3 minutes when 
applied to oozing or bleeding of mild intensity that could not be controlled with 
other surgical techniques [13]. Recombinant human thrombin was examined in a 
similar study that did not include cardiovascular surgery patients, but did include 
vascular surgery procedures and demonstrated comparable results regarding efficacy 
[14]. Both human and recombinant thrombin boast reduced immunologic response 
compared to bovine thrombin. Recombinant thrombin has the added benefit of 
minimizing the theoretical risk of viral transmission compared to human thrombin 
that has been pooled from donor plasma.
An active hemostatic agent such as thrombin is particularly useful in cardiac 
surgery patients where innate coagulation is impaired secondary to systemic hepa-
rinization while on cardiopulmonary bypass. It should be considered for mild to 
moderate non-surgical bleeding (not amenable to suture ligation or electrocautery) 
or in a surgically inaccessible area such as the dome of the left atrium or raw myo-
cardial edges from a deep intra-myocardial coronary following bypass grafting [15]. 
In non-cardiac procedures, instillation of thrombin, complexed with fibrinogen, 
has also been described as an efficacious hemostatic therapy in the management of 
severe hemoptysis (>150 cc/12 hrs) [16]. Although bronchial artery embolization 
(BAE) is the treatment of choice in these patients, this therapy may be unavailable 
and endoscopic fibrinogen-thrombin instillation can serve as a bridge to emboliza-
tion or as primary therapy in its absence.
Thrombin can be delivered alone via a spray applicator, with an inert carrier 
such as a gelatin sponge, or in combination with fibrinogen (fibrin glue). When 
paired with a gelatin component, the sponge is capable of absorbing 45 times its 
own weight, expanding to nearly 200% of its initial volume and facilitating concen-
tration of coagulation factors in the area of concern. Like bovine derived thrombin, 
the gelatin is derived from porcine or bovine sources and carries with it a theoretical 
risk of antigenicity [17]. Caution should be used in applying gelatin sponge based 
thrombin products to open arterial bleeding due to potential risk for embolization. 
Of note, thrombin spray is contraindicated in treating massive or arterial bleeding 
and caution should be exercised to avoid entry into large blood vessels as it can 
produce severe intravascular clotting.
An essential consideration in using thrombin as a topical hemostat, depending 
on its source, is its proper preparation and storage. Both bovine derived and recom-
binant thrombin are available in powder form meaning they require mixing with 
saline to reconstitute into solution for application. They should be stored at room 
temperature [18, 19]. Conversely, human thrombin is packaged in solution and 
stored frozen. It may be left refrigerated for up to 30 days and can be stored at room 
temperature for no more than 24 hours per the manufacturer.
Products such as FloSeal deliver human thrombin (previously bovine) in a 
gelatin-based matrix consisting of collagen microgranules to produce swelling and 
tamponade upon contact with blood. Compared to other fibrin sealants, it requires 
blood as a source of fibrinogen. Similar to standalone pooled human thrombin, 
a theoretical risk of viral transmission exists with utilization of FloSeal despite 
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manufacturer efforts to reduce viral load during production. Regarding efficacy, a 
prospective randomized study compared FloSeal with Gelfoam thrombin after con-
ventional surgical methods failed to control bleeding and demonstrated that FloSeal 
had superior hemostatic efficacy with a comparable safety profile to Gelfoam 
thrombin [20]. The aforementioned study group consisted of patients undergo-
ing cardiac surgery and demonstrated that FloSeal achieved hemostasis in 94% of 
patients compared to 60% in the Gelfoam thrombin control group within 10 min-
utes. This difference was even more pronounced at 3 minutes where hemostasis was 
successful in 72% of the FloSeal group compared to 23% of the control. Similarly, a 
prospective randomized study by Nasso, et al. compared FloSeal to a control group 
of Surgicel or Gelfoam and included patients undergoing cardiac and thoracic aortic 
procedures. They demonstrated statistically higher rates of successful hemostasis, 
shorter times to hemostasis, and lower rates of post-operative transfusion of blood 
products, in the FloSeal group [21]. Common sites of cardiac bleeding treated in the 
study included coronary bypass anastomoses, cardiotomy sites, and anastomotic 
sites involving a prosthesis. The trial likewise found that FloSeal was associated 
with a statistically significant higher rate of successful hemostasis and shorter time 
to hemostasis when compared to the control group. Lower rates of blood product 
transfusion, incidence of re-exploration, and shorter ICU LOS were also appreci-
ated in the group treated with FloSeal, although not statistically significant.
3. Fibrin sealants (Tisseel®)
Fibrin sealants first gained FDA approval in 1989 with the commercial release 
of Tisseel. Fibrin sealants generally contain separated components of freeze dried 
coagulation proteins, mainly fibrinogen and thrombin but also fibronectin. They 
are typically supplied in a dual syringe system that admix the two agents immedi-
ately prior to application. Fibrinogen, of course if a precursor to fibrin, the very 
foundation of the clot and is activated by thrombin, which serves as a catalyst 
when delivered simultaneously. Fibronectin on the other hand, is a high molecular 
weight, extracellular matrix glycoprotein that is physiologically deposited at the site 
of injury along with fibrin and serves as a sealant to aid in wound healing [22]. The 
mechanical strength of the sealant is driven by the concentration of fibrinogen and 
the relative concentration of thrombin determines the rate of clot formation [23]. 
By understanding the individual components of fibrin sealants, it is relatively easy 
to understand how these products mimic the final stages of wound healing and can 
be especially useful in patients with coagulopathies from systemic heparinization 
or other anticoagulants. One prospective randomized clinical trial of fibrin sealant 
versus more conventional hemostatic agents in cardiac surgery patients undergoing 
re-sternotomy or re-exploration identified significant shorter time to hemostasis 
and decreased post-operative blood loss compared to patients in the control group 
[24]. A randomized controlled trial in pediatric patients undergoing cardiac surgery 
with known significant coagulopathy demonstrated intraoperative use of fibrin 
sealant significantly reduced the amount of bleeding and transfusion of blood/
blood products but also decreased the time to hemostasis [25]. Caution should be 
used with fibrin sealants, especially in coronary artery bypass grafting where they 
have been reported to be associated with increased risk of myocardial injury when 
applied intra-operatively. Lamm, et al., describe several cases of acute occlusion 
of coronary bypass grafts after administration of a fibrin sealant near anastomotic 
sites [26]. In each reported case, embolectomy at that time demonstrated fresh 
fibrin clot within the graft. The aforementioned study specifically examined 
Tissucol (Baxter) in aortocoronary bypass operations.
Contemporary Applications of Biologic Hemostatic Agents Across Surgical Specialties Volume 2
6
Applications in general thoracic surgery include intra-operative application of 
fibrin glue for the prevention of prolonged air leak in patients undergoing pul-
monary resection. Air leak can arise from pulmonary parenchyma secondary to 
surgical manipulation or stapling. Generally, these parenchymal air leaks resolve 
spontaneously in a few days. Prolonged air leak (greater than 7 days) is associated 
with increased length of stay and may ultimately require further intervention. 
Studies exploring the efficacy of fibrin glue in the prevention of post-operative air 
leak have yielded mixed results to support their routine use [27, 28, 29].
4. Progel ™
Progel (Bard) is a pleural air leak sealant consisting of polyethylene glycol and 
human serum albumin. It is the only FDA approved product to treat pleural air 
leaks in open thoracotomy, video-assisted, and robotic-assisted thoracic surgery. It 
is delivered in an adjustable syringe applicator providing either a stream for focal 
application to suture/staple lines or as a spray for increased surface area application. 
Progel’s intrinsic elasticity makes it an attractive option for application to the pleural 
surface of the lung with an ability to tolerate re-expansion within 2 minutes of use 
[30]. A multicenter, prospective, randomized control trial demonstrated that intra-
operative application of Progel resulted in fewer post-operative air leaks compared 
to the control group (65% vs. 86%, respectively) and shorter median length of stay 
(6 vs. 7 days, respectively) [31].
5. Evarrest®
Evarrest (Ethicon), is a fibrin sealant patch made of oxidized regenerated 
cellulose covered with thrombin (human derived) and fibrinogen. Contact of the 
powdery, active side of the patch with bleeding tissue causes thrombin to activate 
fibrinogen to fibrin and form a stable clot. The newly formed clot subsequently 
integrates with the patch’s matrix design to assist in achieving hemostasis [32]. 
Advantages of Evarrest include that it is ready to use and bio-absorbable in about 
eight weeks. Contraindications to its use are comparable to other topical active 
agents in that it should not be applied to control bleeding from large vascular 
defects or intravascularly. Like most thrombin containing products, there is also 
risk of reaction to human blood products.
Evarrest has been successfully described in the control of major vascular injury 
during robotic assisted lobectomy and segmentectomy [33]. In the vignette pro-
vided by Gharagozloo et al., pulmonary artery/vein bleeding was controlled with 
direct pressure aided by a tightly rolled gauze sponge wrapped with an Evarrest 
fibrin sealant patch for 3 minutes while seeking to obtain proximal control. Should 
conversion to thoracotomy be required, pressure should continue to be held with 
a non-robotic instrument through the assistant port and allowing for complete 
removal of the robot from the field.
6. BioGlue®
BioGlue is a bovine serum albumin and glutaraldehyde tissue adhesive originally 
developed as an adjunct for hemostasis in cardiovascular surgery, gaining FDA 
approval in 2001. Similar to fibrin sealants, BioGlue’s components are provided in 
two separate vials and delivered via a two-chambered syringe. The two agents are 
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mixed within the applicator tip immediately prior to application. When applied 
to tissue, the glutaraldehyde and albumin form strong covalent crosslinking with 
each other and the tissue at the site. The mechanical seal is not only independent of 
the patient’s intrinsic clotting mechanisms but polymerizes rapidly and adheres to 
synthetic graft materials, making it an attractive option for controlling anastomotic 
bleeding in cardiac and vascular surgery when utilizing synthetic (eg Dacron®, 
Gore-tex®, and polyurethane) grafts or patches. BioGlue requires a bloodless field to 
adhere unlike some other agents, limiting its utility for active bleeding. It is generally 
applied to an anastomotic site in a thin layer prior to unclamping and restoration of 
perfusion [34]. Specific applications in cardiothoracic surgery include [35]:
Repair of type A aortic dissections. Specifically, the re-approximation of dissected 
aortic arch layers.
Aortic root reconstruction. Bovine albumin-glutaraldehyde may be used to seal the 
proximal anastomosis of the LVOT and replaced aortic root. This can be a particu-
larly difficult suture line to place repair sutures.
Left ventricular apical cannulation. BioGlue can be applied when sewing a left 
ventricular assist device cannula cuff to the apex of the left ventricle, an area 
known to be especially prone to bleeding. Sealing this area with bovine albumin- 
glutaraldehyde is particularly useful as it will be under the stress of systolic left 
ventricular pressures and constant motion.
Right/left ventricular tear or rupture repair. BioGlue can be used in conjunction 
with patches of oxidized regenerated cellulose (Surgicel) to support fragile repairs 
of the right ventricle. It can also be used in traumatic ruptures of the left ventricle 
with bovine pericardium instead of Surgicel.
Post-infarction ventricular septal defect repair. BioGlue can be used to seal the 
overlapping Dacron patches of the repair together.
Ensuring hemostasis of suture lines. Particularly when applied to aortic aneurysm 
repairs, coronary anastomoses, and arteriotomies.
Criticism of BioGlue includes its low viscosity and difficulty controlling its 
application. This can be mitigated by injecting slowly and allowing the glue to par-
tially set prior to completely expelling the mixture from the applicator tip. Various 
reports of adverse events have described early failure of coronary artery bypass 
grafts, leaking of glue through needle holes causing embolization, and anastomotic 
stricture impairing aortic growth [36, 37, 38].
7. Bone wax and Ostene ®
Median sternotomy is the most common approach in cardiac surgery. It can also be 
used in non-cardiac thoracic surgery to access the lower trachea, mainstem bronchi, 
tumors of the anterior mediastinum, and retrosternal goiters. The sternum is primar-
ily made of spongy, cancellous bone encased in a rim of cortical bone. Its high surface 
area to volume ratio make it no surprise that it is highly vascular and prone to osseous 
hemorrhage. Bleeding from the median sternotomy of a heparinized patient can be 
challenging to control. Mechanical hemostatic devices such as bone wax can greatly 
aid in providing an impenetrable barrier. The most classic formulation described by 
Sir Victor Horsley in 1885 consisted of beeswax, almond oil and salicylic acid [39]. 
In current use, most surgeons know medical grade bone wax as a non-absorbable 
mixture of sterilized beeswax and a softening agent such as Vaseline or paraffin with 
isopropyl palmate. In use, bone wax is quite malleable and can be worked to any 
desired consistency before application either manually or via submersion in warm, 
sterile solution before removing from the packaging. Despite its relative ease of use, 
there are several significant complications that one should consider.
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First and foremost, experimental studies have demonstrated that bone wax sig-
nificantly reduces the number of bacteria needed to initiate infection [40, 41]. For 
this reason, bone wax should never be utilized in a contaminated field. Secondly,  
bone wax is relatively inert, having been identified as remotely as 10 years follow-
ing initial application. Histological studies have confirmed these suspicions on 
autopsy showing chronic granulomatous inflammation and foreign body reaction 
[42]. Given the above findings, it is understandable how bone wax could complicate 
healing of the sternum following median sternotomy by not only increasing risk of 
mediastinitis and osteomyelitis but impairing sternal edge apposition and inducing 
chronic inflammation.
Ostene, like bone wax, readily provides hemostasis without impairing bone 
healing. It was originally described in 2001 as an absorbable alternative to bone 
wax. Ostene is water-soluble and composed of hydrophilic alkylene oxide copo-
lymers and is eliminated from the bone surface within 24–48 hours of application 
[43]. Several studies have compared Ostene to bone wax regarding sternal healing 
and favor its use to reduce sternal dehiscence and chronic inflammation [44, 45].
8. Surgicel®
The Surgicel family of products utilize oxidized, regenerated cellulose delivered 
in a loosely knit sheet, fibrillar sheet, or powder to aid in providing local hemo-
stasis from capillary or minor venous bleeding. They are non-active mechanical 
hemostatic agents, meaning they do not contain specific coagulation factors and are 
best served in patients with intact innate coagulation (ie not on cardiopulmonary 
bypass). Once saturated with blood, Surgicel swells in to a brown-black gelatinous 
mass because of the decreased local pH initiating red cell lysis. It then serves as 
a scaffold for platelet aggregation and is generally absorbed completely within 
4–6 weeks [46]. Surgicel has the added advantage of being bacteriostatic with some 
activity against MRSA reported [47, 48]. One underestimated feature of Surgicel 
is its ease of handling and non-adherence to instruments. However, like most 
hemostatic agents, caution should be exercised with its use. A key disadvantage 
of Surgicel is that by lowering the local pH, other active hemostatic agents may be 
rendered ineffective, namely thrombin [49]. Other authors have reported Surgicel 
remnants being misdiagnosed as an abscess, even mimicking mediastinitis that may 
be difficult or impossible to distinguish on imaging [50].
Surgicel is commonly applied in video-assisted thorascopic surgery during 
lymphadenectomy. In general, bleeding from lymphadenectomy can be avoided 
with careful dissection in avascular planes. However, occasional entry into the 
lymph node capsule introduces troublesome but non-life threatening bleeding 
that can easily be controlled using direct pressure with a topical hemostat such 
as Surgicel [51]. Typically bleeding improves following lymph node removal, but 
Surgicel may be left in the lymph node basin for any mild persistent bleeding.
9.  Microporous polysaccharide hemospheres (Arista™ Absorbable 
Hemostat)
Arista AH (Bard) is a microporous polysaccharide hemosphere (MPH) powder 
derived from purified plant starch with FDA approval for not only cardiothoracic 
but vascular, gynecological, urology, orthopedic, general, plastic and ENT surgeries 
as well. Notably, Arista has been FDA approved as a cell saver, or autologous blood 
salvage circuit, compatible hemostat. Arista rapidly dehydrates blood, causing the 
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MPH particles to swell and concentrate blood solids such as platelets, RBCs, and 
coagulation proteins to form a gelled matrix [52]. This gelatinous matrix creates 
a scaffold for formation of the fibrin clot and provides a mechanical barrier to 
continued blood loss regardless of the patient’s coagulation status. Arista is typi-
cally enzymatically degraded by serum amylases and cleared from the body within 
24–48 hours per the manufacturer. To apply, the area of concern should have as 
much excess blood removed as possible, Arista should be liberally applied to the site 
of bleeding, wound-appropriate pressure should be held, and excess Arista should 
be removed by irrigation. Like most hemostatic agents, it should not be placed in 
blood vessels or when there may be risk of embolization. A retrospective study 
by Bruckner, et al., compared the application of topical Arista to historical agents 
including FloSeal, Gelfoam thrombin, or Surgicel in cardiothoracic procedures. 
They found a decreased time to hemostasis, decreased post-operative blood loss, 
and reduced blood product transfusion requirement within the first 48 hours post-
operatively without any identified adverse events.
10. Conclusion
Bleeding in the cardiothoracic surgery patient is well studied. Specifically, cardiac 
surgery patients are frequently subject to systemic heparinization and potentially 
multiple antiplatelet medications. Thus, significantly increasing their risk for nonspe-
cific bleeding refractory to traditional surgical hemostatic maneuvers. Complications 
from uncontrolled bleeding are both costly to the patient in terms of outcomes and 
economically to the healthcare system as well. Selection of the proper hemostatic 
adjunct can reduce time to hemostasis, blood product transfusion, and improve 
patient outcomes. Frequently, selection of a hemostatic agent has been constrained by 
anecdotal experience and limited knowledge of the diverse array of agents presently 
available. Choosing a hemostatic adjunct relies on understanding of its mechanism 
of action, indications for use, and knowledge of potential complications surrounding 
its use. In addition, many topical hemostats have also found novel uses in non-cardiac 
thoracic surgery to reduce post-operative air leaks and length of stay following 
pulmonary resection. The prepared surgeon has familiarized themselves with these 
agents and can anticipate opportunities for their deployment.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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